The World’s Lab Bench

Behind a great many Western drugs sits a Chinese contract lab or factory. Firms like WuXi AppTec and WuXi Biologics have become deeply woven into the global pharmaceutical supply chain, discovering, testing and manufacturing medicines for companies whose names are on the box. WuXi Biologics alone held around 10% of the global biologics-outsourcing market and counts every one of the top twenty pharma companies as a client.^[2]

The dependence is real enough to alarm Washington. WuXi AppTec draws roughly 62% of its revenue from the United States, and even amid political threats it added more than 500 new customers in the first half of 2024 on top of a base exceeding 6,000, a sign that US biopharma could not easily unplug.^[3][4]

The law that was written to name China’s biggest labs, in the end, named no one. The list comes later.

A law with a blank list

The political response was the BIOSECURE Act, and its final form is widely misdescribed. An earlier 2024 bill explicitly named WuXi AppTec, WuXi Biologics, BGI, MGI and Complete Genomics as companies of concern. But the version enacted in December 2025, folded into the annual defence bill, names none of them; instead it directs the White House budget office to publish an official list of “biotechnology companies of concern” within a year, after which federal contracting restrictions, with a five-year grandfathering window, would apply.^[1] The threat is real but deferred and conditional; it is not accurate to say the law bans WuXi today.

That nuance is the whole story for now. The naming that would actually bite has been handed to a future administrative process, leaving the affected firms in a state of strategic limbo rather than immediate exclusion.^[1]

Reading it as an investor

The CRO/CDMO story is where Chinese capability and geopolitical risk collide most directly, and the enacted-but-unnamed status of BIOSECURE is exactly the kind of detail that separates careful analysis from headline-trading. The deep dependence is genuine and slow to unwind, which supports the incumbents; the legislative overhang is real but contingent on a list not yet written, which caps the certainty in either direction. We watch the forthcoming “companies of concern” designations as the actual catalyst, treat the five-year grandfathering as a long runway rather than a cliff, and price the whole sector as a bet on how fast, and how specifically, decoupling is actually legislated, not on the headline that a law passed.